Follow
Michael J Dolton
Title
Cited by
Cited by
Year
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring
MJ Dolton, JE Ray, SCA Chen, K Ng, LG Pont, AJ McLachlan
Antimicrobial agents and chemotherapy 56 (9), 4793-4799, 2012
3442012
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration
MJ Dolton, JE Ray, SCA Chen, K Ng, L Pont, AJ McLachlan
Antimicrobial agents and chemotherapy 56 (11), 5503-5510, 2012
2012012
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial
SG Kelsen, IO Agache, W Soong, E Israel, GL Chupp, DS Cheung, ...
Journal of allergy and clinical immunology 148 (3), 790-798, 2021
1912021
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring
MJ Dolton, JE Ray, D Marriott, AJ McLachlan
Antimicrobial agents and chemotherapy 56 (6), 2806-2813, 2012
1642012
Voriconazole pharmacokinetics and exposure–response relationships: assessing the links between exposure, efficacy and toxicity
MJ Dolton, AJ McLachlan
International journal of antimicrobial agents 44 (3), 183-193, 2014
1082014
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
MJ Dolton, G Mikus, J Weiss, JE Ray, AJ McLachlan
Journal of Antimicrobial Chemotherapy 69 (6), 1633-1641, 2014
1062014
Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial
E Teng, PT Manser, K Pickthorn, F Brunstein, M Blendstrup, ...
JAMA neurology 79 (8), 758-767, 2022
992022
Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials
S Ostrowitzki, T Bittner, KM Sink, H Mackey, C Rabe, LS Honig, ...
JAMA neurology 79 (11), 1113-1121, 2022
982022
Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion–Transporting Polypeptides
MJ Dolton, BD Roufogalis, AJ McLachlan
Clinical Pharmacology & Therapeutics 92 (5), 622-630, 2012
932012
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis
MJ Dolton, RJM Brüggemann, DM Burger, AJ McLachlan
Antimicrobial agents and chemotherapy 58 (11), 6879-6885, 2014
832014
Vancomycin pharmacokinetics in patients with severe burn injuries
M Dolton, H Xu, E Cheong, P Maitz, P Kennedy, T Gottlieb, E Buono, ...
Burns 36 (4), 469-476, 2010
832010
Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations
PJ Colin, K Allegaert, AH Thomson, DJ Touw, M Dolton, M de Hoog, ...
Clinical pharmacokinetics 58, 767-780, 2019
772019
Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks
H Guthrie, LS Honig, H Lin, KM Sink, K Blondeau, A Quartino, M Dolton, ...
Journal of Alzheimer's disease 76 (3), 967-979, 2020
502020
Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based …
MJ Dolton, V Perera, LG Pont, AJ McLachlan
Antimicrobial agents and chemotherapy 58 (1), 48-54, 2014
462014
Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections
MJ Dolton, AJ McLachlan
Current opinion in infectious diseases 27 (6), 493-500, 2014
352014
Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet
C Monteiro, B Toth, F Brunstein, A Bobbala, S Datta, R Ceniceros, ...
Neurology 101 (14), e1391-e1401, 2023
282023
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis
M Maurer, DS Cheung, W Theess, X Yang, M Dolton, A Guttman, DF Choy, ...
Journal of Allergy and Clinical Immunology 150 (6), 1517-1524, 2022
272022
Comparative evaluation of the predictive performances of three different structural population pharmacokinetic models to predict future voriconazole concentrations
A Farkas, G Daroczi, P Villasurda, M Dolton, M Nakagaki, JA Roberts
Antimicrobial Agents and Chemotherapy 60 (11), 6806-6812, 2016
252016
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice
V Perera, RR Bies, G Mo, MJ Dolton, VJ Carr, AJ McLachlan, RO Day, ...
British Journal of Clinical Pharmacology 78 (4), 800-814, 2014
212014
Clinical importance of the CYP2C19* 17 variant allele for voriconazole
MJ Dolton, AJ McLachlan
British journal of clinical pharmacology 71 (1), 137, 2011
202011
The system can't perform the operation now. Try again later.
Articles 1–20